Aethlon Medical Inc (AEMD)

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®June 26, 2026 8:01 AM
PR Newswire (US) Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatmentSAN DIEGO, June 26, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier®.The study, conducted in collaboration with investigators from the University of California, San Francisco (UCSF), provides what we believe is new evidence supporting extracellular vesicles as a potential therapeutic target in Long COVID and helps establish a translational framework for future studies evaluating whether the Hemopurifier can remove disease-associated EVs and their molecular cargo."The publication of this study contributes to the scientific understanding of the biological mechanisms underlying Long COVID while strengthening the rationale for evaluating the Hemopurifier in this significant area of unmet medical need," said Jim Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "While the Company's current resources and primary focus remain dedicated to advancing our Australian oncology clinical trial, these findings provide additional translational evidence supporting future preclinical and clinical studies designed to determine whether removal of these circulating extracellular vesicles may benefit patients with Long COVID. More broadly, we believe these findings reinforce the potential of the Hemopurifier as a platform technology with potential applications across multiple disease areas.  We believe there exists a 'pipeline within a single device.'"Key FindingsAmong the study's principal findings:Patients with Long COVID had approximately two-fold higher levels of mannose-positive extracellular vesicles than individuals who recovered fully following COVID-19 infection.Small extracellular vesicles carrying disease-associated glycosylation patterns were successfully captured using GNA affinity resin, the active binding component of the Hemopurifier.GNA affinity resin treatment significantly reduced seven circulating microRNAs associated with immune regulation and inflammatory signaling.Computational pathway analysis suggested modulation of several biologically relevant signaling pathways implicated in Long COVID, including JAK-STAT, VEGF, PI3K, and Estrogen signaling.The findings help establish a mechanistic link between disease-associated extracellular vesicles and the Hemopurifier's lectin-based capture technology.The research analyzed plasma samples from participants enrolled in UCSF's Long-term Impact of Infection with Novel Coronavirus (LIINC) study.The full peer-reviewed article, titled "Increased Mannosylation of Extracellular Vesicles in Long COVID Plasma as a Binding Target for Galanthus nivalis Agglutinin (GNA) Affinity Resin," appears in the International Journal of Molecular Sciences at https://www.mdpi.com/1422-0067/27/13/5723About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device that is designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses, and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.Additional information can be found at www.AethlonMedical.com.Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to determine whether the Hemopurifier has utility in additional disease indications, including Long COVID; the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the ability of the Hemopurifier to continue to show removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment; the manuscript described in this release being under review and may be rejected for publication, require substantial revision, or be interpreted differently by the scientific community; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia, including on the timing expected by the Company; the Company's ability to continue its oncology clinical trial in Australia, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. The preclinical findings described herein are preliminary in nature and may not be replicated in subsequent studies or clinical trials.Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.comInvestor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com  View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-publication-demonstrating-novel-long-covid-biomarker-and-potential-therapeutic-target-for-the-hemopurifier-302811447.htmlSOURCE Aethlon Medical, Inc. Original: Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola OutbreakJune 26, 2026 7:00 AM
NewsfileVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak.From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola OutbreakTo view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6292/302945_25531c9754dd1b93_001full.jpgAccording to a recent ABC news headline - "France confirms 1st Ebola case linked to DRC as UN warns outbreak is fastest-growing in Africa's history. The outbreak has led to more than 1,000 cases and more than 260 deaths."UN news reports – "Ebola has been spreading at unprecedented speed in the eastern Democratic Republic of the Congo (DRC), bringing risk and fear into people's daily lives, UN humanitarians said on Tuesday."From big pharma to smaller players, stocks in the sector are making headlines as the outbreak continues. Biotech and biodefense stocks focusing on infectious diseases like Ebola can be highly speculative and the sector has already experienced volatility. Soligenix (NASDAQ: SNGX) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported June 8th that the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due June 12, 2026. Soligenix, in collaboration with Axel Lehrer, PhD, Professor in the Department of Tropical Medicine, Medical Microbiology and Pharmacology at the John A. Burns School of Medicine, University of Hawai?i at Manoa, has previously developed bivalent and trivalent thermostable vaccines, constructed from antigens against Ebola virus, Sudan virus and Marburg virus and the CoVaccine HT™ adjuvant, demonstrating thermostability, immunogenicity and durable efficacy in non-human primates. This work, combined with previous and ongoing work in Dr. Lehrer's laboratory that has demonstrated platform compatibility of the key Bundibugyo virus antigen, will form the basis of an application to CEPI enabling rapid development of a protein-based thermostable subunit vaccine for BDBV.From the news:
"Our filovirus vaccines have demonstrated broad and robust immune responses in mice and up to 100% protection in non-human primates," stated Dr. Lehrer. "Further, we have developed thermostable vaccine formulations in collaboration with Soligenix, demonstrating extended stability that is particularly relevant for the use of these vaccines in virus-endemic countries in Africa, as well as in the context of strategic national stockpiles and preparations for potential larger outbreaks and pandemics. A single-vial subunit vaccine that can be shipped at ambient temperatures and then needs to only be reconstituted with sterile water immediately prior to use has the potential to improve vaccination efforts globally by simplifying storage and distribution logistics not only as a stand-alone vaccine, but also as a practical add-on booster broadening immunity in persons previously or concurrently vaccinated with other vaccines. We look forward to submitting this application with the aim of rapidly advancing the BDBV vaccine and the multivalent platform in general."Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases recently announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda, and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology.Aethlon's Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. During the 2014 Ebola (Zaire strain) outbreak, the Hemopurifier was successfully administered to a critically ill Ugandan physician treated at Frankfurt University Hospital under emergency-use circumstances. At the time Hemopurifier therapy was initiated, the physician was unconscious and suffering from multiple organ failure requiring mechanical ventilation, vasopressor support and continuous dialysis. Following a single 6.5-hour Hemopurifier treatment, the patient's viral load reportedly declined from approximately 400,000 Ebola virus copies per milliliter of blood to approximately 1,000 copies per milliliter of blood. The Ebola virus subsequently became undetectable five days following treatment. Testing performed after this treatment indicated that the Hemopurifier captured Ebola virus during therapy; quantitative estimates reported at the time, were approximately 242 million virions. The patient ultimately made recovered and returned home to Uganda.In its recent earnings conference call, Aethlon noted that it has shared information regarding its Ebola-related research, clinical experience, and regulatory status with the World Health Organization's R&D Blueprint Expert Panel and the National Emerging Special Pathogens Training and Education Center (NETEC), which works closely with the 13 U.S. regional special pathogen treatment centers that would treat an Ebola patient in the United States should one occur.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced in May that maftivimab, the most potent neutralizing antibody included in Inmazeb® (maftivimab, atoltivimab and odesivimab-ebgn), has been recommended by the World Health Organization's (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo.From the news:
The trial pertains to the WHO's recent declaration that the current outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda constitutes a public health emergency of international concern. WHO is now working closely with the governments of DRC and Uganda to facilitate the implementation of research evaluations of the prioritized products."We are closely coordinating our efforts with the U.S. Department of Health and Human Services (HHS) and look forward to working with the World Health Organization and others as clinical evaluation moves ahead," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. "Regeneron has a track record of rapidly delivering important medical solutions during times of global health crisis, such as the COVID-19 pandemic and multiple Ebola outbreaks, and we know that independently run and locally executed clinical trials are critical to developing effective new medicines in such situations."Inmazeb is already approved by the U.S. Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, also known as Zaire ebolavirus, in adult and pediatric patients, including neonates born to infected mothers. Maftivimab is the most potent virus-neutralizing component of Inmazeb and has demonstrated broad neutralizing activity in laboratory studies against Bundibugyo ebolavirus; it has not yet been tested in vivo as a monotherapy against this distinct Ebola virus. Maftivimab has been administered to hundreds of human patients as a component of Inmazeb, which has demonstrated an acceptable safety profile. Since 2018, Inmazeb has been offered by Regeneron at no cost under a compassionate use protocol to infected persons in countries experiencing an Orthoebolavirus zairense outbreak, including the DRC and Guinea. On June 1, Moderna, Inc. (NASDAQ: MRNA) announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.From the news:
Under the agreement, CEPI has committed up to US $50 million to support preclinical development and Phase 1 clinical testing of Moderna's investigational BDBV vaccine candidate. The funding will also support parallel manufacturing activities, enabling doses to be produced while clinical evaluation is underway and positioning the program to rapidly advance into large-scale Phase 2/3 trials should the Phase 1 safety and immunogenicity data support further development.The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic. The program also builds on Moderna's existing research and development efforts in filoviruses, including Ebola-related viruses.The collaboration further expands Moderna's longstanding strategic collaboration with CEPI, which is focused on accelerating the development of vaccines and other countermeasures against epidemic and pandemic threats."At Moderna, we believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," said Stéphane Bancel, Chief Executive Officer of Moderna. "We are proud to expand our strategic collaboration with CEPI to advance a potential vaccine candidate against Bundibugyo ebolavirus, leveraging our established technology and experience in filovirus vaccine development. We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."By combining CEPI's funding and expertise in epidemic preparedness with Moderna's mRNA platform and manufacturing capabilities, the collaboration aims to accelerate the development of a potential vaccine that could help strengthen global readiness against future Ebola outbreaks."With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," said Dr. Richard Hatchett, CEO of CEPI. "CEPI's urgent funding and support aims to advance safe, effective vaccines to help control this epidemic."Disclaimer/Disclosure: Disclaimer: Biotech and biodefense stocks focusing on infectious diseases can be highly speculative and carry significant volatility. Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas. More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.Research biotech stocks at Investorideas.com:
https://www.investorideas.com/Companies/RenewableEnergy/stock_list.aspAbout Investorideas.com – Where you find the best investing ideas Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.Investor Ideas digital advertising and guest posts service :
https://www.investorideas.com/Advertise/Follow us on X @investorideas @stocknewsbites
Follow us on Facebook https://www.facebook.com/Investorideas
Follow Investorideas on YouTube https://www.youtube.com/c/InvestorideasJoin our free Telegram community
https://t.me/+o8DxSAgeNCk2ZGVhContact us for more info
Call 800 665 0411 To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302945 Original: From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak

Steady zero borrow,they holding on tight to all their shares,something is coming,expect news soon

In 1.42 ,hit zero borrow today from 500k yesterday

Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate UpdateJune 10, 2026 4:15 PM
PR Newswire (US) Australian oncology study advances into Cohort 3 as enrollment continuesEntered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses.Conference Call Today at 4:30 p.m. ETSAN DIEGO, June 10, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments. Key HighlightsAdvanced the Australian oncology study through completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generating data to inform future development and dosing strategy.Recently treated the first participant in Cohort 3 at Royal North Shore Hospital in Australia. The participant completed three Hemopurifier treatments over a one-week period, marking continued enrollment momentum and execution of the study's final treatment arm. Advanced preclinical research evaluating Hemopurifier applications in additional disease areas, including rheumatoid arthritis and chronic kidney disease, supporting the expansion of the platform's potential addressable market beyond oncology and infectious disease.Continued to strengthen the intellectual property portfolio supporting the Hemopurifier platform, including the issuance of patents in the United States and Europe covering potential applications for long COVID and other coronavirus-related conditions, extending patent protection into the 2040s and enhancing long-term platform value."Fiscal 2026 was a year of meaningful execution for Aethlon as we advanced our Australian oncology study through the first two cohorts and recently initiated Cohort 3. Advancement into the final cohort represents an important clinical milestone as we work toward generating data that may help define the optimal treatment regimen and guide future development decisions. We also strengthened the Hemopurifier platform through expansion of our intellectual property portfolio and advancement of preclinical research supporting potential applications beyond oncology. Combined with our continued focus on managing operating expenses, these achievements position us to pursue multiple value-creating opportunities across our clinical and research programs." said James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical.Clinical UpdateClinical Progress in Cancer TrialEnrollment and treatment of participants in Cohort 2 of the Australian oncology trial have been completed. An independent Data Safety Monitoring Board reviewed the data, identified no safety concerns based on its review of available data, and recommended advancing to the third and final cohort. Screening is actively underway at the three investigative sites for this final cohort where 3-6 participants will be treated with 3 Hemopurifier sessions during a 1-week period. The first participant in Cohort 3 of the study has been enrolled and received three Hemopurifier treatments without any device deficiencies or immediate complications and is now in the follow-up period. Successful enrollment and treatment of the first participant in Cohort 3 maintains the study's clinical momentum and moves the Company closer to completing enrollment and generating data from all planned dosing regimens.Serial Extracellular Vesicle and T cell measurements on participants in cohort 2 have been measured by the central lab at the University of Sydney. Formal statistical analyses comparing the effects of the three different Hemopurifier dosing regimens on these parameters will be performed by a CRO at the completion of the trial. This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®.Other Recent DevelopmentsDuring fiscal 2026, we strengthened our intellectual property portfolio through the issuance of patents in both the United States and Europe covering 2 potential applications of the Hemopurifier for coronavirus-related conditions; excessive clotting known as coagulopathy during acute COVID-19 infection and symptoms of Long COVID. These patents extend protection for certain applications of the Hemopurifier into the 2040s.In addition, we advanced our preclinical extracellular vesicle (EV) research activities, including studies evaluating removal of EVs in plasma samples from patients with rheumatoid arthritis and chronic kidney disease. These efforts support the Company's ongoing evaluation of the Hemopurifier's potential applications across multiple disease categories and may create future opportunities to expand the platform into large markets characterized by significant unmet medical need.Separately, we continued our evaluation of Hemopurifier compatibility with a simplified blood treatment system being developed by Stavro Medical. Initial testing assessing flow rates and transfer of fluid through the Hemopurifier has been completed, and future studies evaluating removal of surrogate markers for extracellular vesicles by the Hemopurifier using the system are under consideration. We believe this approach could expand potential treatment settings for the Hemopurifier in the future and may improve the scalability and accessibility of treatment if successfully developed and validated.Subsequent to fiscal year-end, an interview published in IEEE Spectrum featuring Aethlon's Chief Medical Officer and a physician involved in the treatment of an Ebola virus disease patient with the Hemopurifier during the 2014 outbreak highlighted the Company's experience with Ebola treatment efforts. In connection with renewed public health interest surrounding recent Ebola outbreaks, we also confirmed the continued availability of our FDA-authorized expanded access (compassionate use) protocol and shared the protocol as well as past in vitro and in vivo data with organizations involved in global and U.S. emerging pathogen preparedness efforts, including the World Health Organization's R&D Blueprint expert panel and the National Emerging Special Pathogen Training and Education Center.Financial Results for the Fiscal Year Ended March 31, 2026As of March 31, 2026, the Company had approximately $5.0 million in cash and cash equivalents, providing resources to support ongoing clinical and research activities.Subsequent to fiscal year-end, the Company strengthened its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program.Consolidated operating expenses declined 21.9% year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company's clinical and research priorities compared to $9.3 million for the fiscal year ended March 31, 2025. The decrease was primarily due to $1.1 million reduction in payroll and related expenses, a $500,000 reduction in general and administrative expenses and a $400,000 reduction in professional fees.Consistent with the reduction in operating expenses, the operating loss for the fiscal year decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year.Other income was approximately $142,000 for the fiscal year ended March 31, 2026, primarily reflecting interest income earned on cash balances, compared to other expense of approximately $4 million in the prior fiscal year. The prior-year amount included approximately $4.7 million of non-cash financing-related charges.Net loss attributable to our common stockholders was $7.2 million for the fiscal year ended March 31, 2026, compared to net loss of $13.4 million for the fiscal year ended March 31, 2025.The consolidated balance sheets for March 31, 2026, and March 31, 2025, and the consolidated statements of operations for the fiscal years ended March 31, 2026, and 2025, are included at the end of this release.Conference CallManagement will host a conference call today, Wednesday, June 10, 2026, at 4:30 p.m. ET to review the Company's financial results and recent corporate developments. Following management's formal remarks, there will be a question-and-answer session.Interested parties can register for the conference call by navigating to  https://dpregister.com/sreg/10209612/1042263e8ec.  Please note that registered participants will receive their dial-in number upon registration.Interested parties without internet access or unable to pre-register may dial in by calling:PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442All callers should ask for the Aethlon Medical, Inc. conference call.A replay of the call will be available approximately one hour after the end of the call through July 10, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 7883435.About the Hemopurifier®The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for:The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.About Aethlon Medical, Inc.Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company's ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia; the timing, scope, design, and potential outcomes or interpretation of such studies; the Company's ability to manufacture the Hemopurifier in sufficient quantities for clinical and potential future commercial use; the availability and adequacy of capital to support ongoing operations; statements regarding the Company's Ebola-related compassionate use activities and any resulting interest from public health organizations; the Company's collaborative research activities, including rheumatoid arthritis, chronic kidney disease, and other extracellular vesicle- associated conditions;  and the Company's ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to maintain its Nasdaq listing, the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters. Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.comInvestor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com AETHLON MEDICAL, INC. AND SUBSIDIARY
Consolidated Balance Sheets
Unaudited
ASSETS









March 31, 2026
March 31, 2025
CURRENT ASSETS





  Cash and cash equivalents
$                  5,026,458
$                          5,501,261

  Deferred offering costs
210,985
-

  Prepaid expenses and other current assets
332,094
448,539







TOTAL CURRENT ASSETS
5,569,537
5,949,800








  Property and equipment, net
356,822
676,220

  Operating lease right-of-use asset, net
307,820
601,846

  Patents, net
-
550

  Restricted cash
98,928
97,813

  Deposits
-
33,305







TOTAL ASSETS
$                  6,333,107
$                          7,359,534














LIABILITIES AND STOCKHOLDERS' EQUITY






CURRENT LIABILITIES





  Accounts payable 
$                     384,550
$                            534,524

  Due to related parties
68,250
579,565

  Operating lease liability, current portion
336,718
313,033

  Other current liabilities
657,317
472,164







TOTAL CURRENT LIABILITIES
1,446,835
1,899,286








  Operating lease liability, less current portion
-
336,718







TOTAL LIABILITIES
1,446,835
2,236,004







STOCKHOLDERS' EQUITY












 Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2026
  and 6,000,000 authorized at March 31, 2025; 1,570,449 shares issued and outstanding
  at March 31, 2026 and 258,531 shares issued and 201,074 outstanding at March 31,
  2025
1,570
259

  Additional paid-in capital
180,023,691
173,095,221

  Accumulated other comprehensive loss
(32,703)
(17,133)

  Accumulated deficit
(175,106,286)
(167,954,817)







TOTAL STOCKHOLDERS' EQUITY 
4,886,272
5,123,530







TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$                  6,333,107
$                          7,359,534

AETHLON MEDICAL, INC. AND SUBSIDIARY Consolidated Statements of Operations and Comprehensive LossFor the fiscal years ended March 31, 2026 and 2025Unaudited






Fiscal Year
Fiscal Year

Ended 3/31/26
Ended 3/31/25




OPERATING EXPENSES



  Professional fees
$     1,809,181
$     2,224,092  Payroll and related expenses
2,788,005
3,874,092  General and administrative
2,696,445
3,243,181        Total operating expenses
7,293,631
9,341,365




OPERATING LOSS
(7,293,631)
(9,341,365)




OTHER INCOME (EXPENSE), NET



     Interest income
156,534
298,122     Other income
-
324,450     Interest expense
(14,372)
(10,109)     Other expense
-
(4,659,188)       Total other income (expense), net
142,162
(4,046,725)




NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS
(7,151,469)
(13,388,090)




Basic and diluted net loss per share attributable to common stockholders
$          (10.61)
$          (85.77)




Weighted average number of common shares outstanding - basic and diluted
673,945
156,085




NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS
(7,151,469)
(13,388,090)




OTHER COMPREHENSIVE LOSS
(15,570)
(10,193)




COMPREHENSIVE LOSS
$   (7,167,039)
$ (13,398,283) View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-fiscal-year-end-march-31-2026-financial-results-and-corporate-update-302795934.htmlSOURCE Aethlon Medical, Inc. Original: Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

The founder of AEMD is Jim Joyce and he was CEO. He oversaw the development of the Ebola treatment. H enow has the next generation of the device: https://richardacavalli.wixsite.com/greenplanetmicrocaps/sigy-ebola-plus

A lot of nasty politics has kept this down along with many others. Will it take a pandemic for change to happen?
FDA is eating a lot of crow lately. More coming, and as this happens AM should benefit greatly.

Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic PreparednessMay 21, 2026 8:01 AM
PR Newswire (US) SAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology.According to recent reports from the World Health Organization ("WHO") and other public health agencies, the current outbreak has been identified as involving the Bundibugyo strain of Ebola virus, a strain for which we are not aware of any approved treatments beyond supportive care, as of the date of this release. Health authorities continue to express concern regarding cross-border transmission and the potential for broader regional spread. Public health assessments, including regarding potential cross-border transmission, are evolving and subject to change.Aethlon's Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. During the 2014 Ebola (Zaire strain) outbreak, the Hemopurifier was successfully administered to a critically ill Ugandan physician treated at Frankfurt University Hospital under emergency-use circumstances.At the time Hemopurifier therapy was initiated, the physician was unconscious and suffering from multiple organ failure requiring mechanical ventilation, vasopressor support and continuous dialysis. Following a single 6.5-hour Hemopurifier treatment, the patient's viral load reportedly declined from approximately 400,000 Ebola virus copies per milliliter of blood to approximately 1,000 copies per milliliter of blood. The Ebola virus subsequently became undetectable five days following treatment. Testing performed after this treatment indicated that the Hemopurifier captured Ebola virus during therapy; quantitative estimates reported at the time, were approximately 242 million virions. The patient ultimately made recovered and returned home to Uganda.That treatment data was presented at the American Society of Nephrology Annual Meeting on November 14, 2014 by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital.In the United States, Hemopurifier therapy has previously been made available for Ebola patients through FDA expanded access emergency-use provisions applicable to life-threatening circumstances where alternative therapies may not be available. In January 2015, the U.S. Food and Drug Administration approved an Investigational Device Exemption ("IDE") supplement that established a regulatory pathway for the potential investigational use of Hemopurifier therapy in Ebola-infected individuals in the United States, subject to applicable institutional approvals and patient protection procedures.Investigational use of medical technologies such as the Hemopurifier may proceed through physician-directed emergency and compassionate-use procedures subject to applicable hospital and regulatory oversight."We believe the current Ebola outbreak reinforces the ongoing need for broad-spectrum therapeutic approaches capable of addressing viral threats where approved drug therapies or vaccines may be limited," stated James B. Frakes, Chief Executive Officer of Aethlon Medical. "While the Hemopurifier remains investigational for Ebola treatment, the prior clinical experience on one patient in Germany demonstrated the potential for rapid viral reduction in a critically ill patient under emergency-use conditions."The Company stated that it will continue to monitor the evolving Ebola situation and will respond to questions or requests from treating clinicians.About the Hemopurifier®The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for:The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; andThe treatment of life-threatening viruses not addressed with approved therapies.The Hemopurifier is being developed under an open IDE for both indications.About Aethlon Medical, Inc.Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information visit www.AethlonMedical.com and follow the company on LinkedIn.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this press release include but are not limited to statements regarding Aethlon's active monitoring of developments related to the current Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda; potential engagement and responsiveness to inquiries from treating clinicians and hospitals; potential interactions with global healthcare and regulatory authorities concerning potential investigational use of the Hemopurifier technology; the investigational status of the Hemopurifier for Ebola; references to prior emergency-use and FDA expanded access pathways; and the Company's development plans, regulatory pathway, and potential applications of the Hemopurifier, including its Breakthrough Device designation and ongoing development under an (IDE for oncology and life-threatening viral indications. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the need for and availability of physician-directed emergency or compassionate-use procedures; the requirement for and timing of applicable hospital and regulatory oversight, including institutional approvals and patient protection procedures; uncertainties inherent in investigational use of medical technologies; device performance, deficiencies, or immediate complications; clinical operations, logistics, and timing (including enrollment and access to eligible patients); the status of alternative therapies or supportive care; and the Company's development plans, regulatory pathway, and potential applications of the Hemopurifier. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Breakthrough Device designation expedites interaction with FDA but does not represent FDA clearance or approval and does not, by itself, establish safety or effectiveness. The findings described herein are preliminary in nature, have not been peer-reviewed, and may not be replicated in subsequent studies or clinical trials. Additional data would be required to assess safety and effectiveness.Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.comInvestor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com View original content:https://www.prnewswire.com/news-releases/aethlon-medical-monitoring-current-ebola-outbreak-and-reaffirms-outbreakpandemic-preparedness-302778705.htmlSOURCE Aethlon Medical, Inc. Original: Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness

Advancements in Novel Immunotherapeutics in The Oncology BattleMarch 24, 2026 10:30 AM
NewsfileVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications.Advancements in Novel Immunotherapeutics in The Oncology BattleTo view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6292/289695_0e46dab6145c8910_001full.jpgNovel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune system to precisely target cancer cells.The novel immunotherapeutics market is experiencing rapid growth, valued at approximately USD 150-168 billion in 2025 and projected to exceed USD 300 billion by 2033-2035.Developing a Novel Immunotherapeutic Device to combat cancer and life-threatening viral Infections, Aethlon Medical, Inc. (NASDAQ: AEMD) just announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial, AEMD-2022-06, has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure."From the news:
The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab," is being conducted to assess the Hemopurifier's safety, feasibility, and optimal dosing.The DSMB- comprised of independent medical experts in nephrology and oncology- reviewed data from participants enrolled in the second cohort, in which patients received two Hemopurifier treatments over a one-week period. Based on their evaluation, the DSMB found no safety concerns and confirmed that the Hemopurifier continues to demonstrate a favorable safety and tolerability profile. To date, no serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs) related to the Hemopurifier device or treatment have been reported. "The DSMB's continued positive recommendation supports the safety profile observed to date and allows us to advance into the third and final cohort of this study," said Steven LaRosa, M.D, Chief Medical Officer of Aethlon Medical. "We are encouraged by the gathering momentum of the trial and having a final data set and clinical study report to share with potential investors, partners and regulatory agencies."Enrollment for Cohort 3 is now open. In this final cohort, participants will receive three Hemopurifier treatments over a one-week period further evaluating safety, feasibility and dosing parameters at the study's three active clinical sites in Australia. This trial is designed to enroll approximately 9 to 18-patients with solid tumors who have stable or progressive disease, while receiving treatment that includes Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®). The primary endpoint of this trial is the incidence of adverse events and clinically significant changes in safety laboratory tests of Hemopurifier- treated patients. In addition to safety monitoring, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of extracellular vesicles (EVs) and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These findings are expected to inform the design of a future efficacy and safety, Premarket Approval (PMA), study required by regulatory authorities.Aethlon Medical, Inc. remains committed to advancing the Hemopurifier for use in oncology and will continue to provide updates as the clinical trial progresses.The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects. TuHURA Biosciences, Inc. (NASDAQ: HURA), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, just announced Dr. Craig L. Tendler will provide strategic, operational and other related services consistent with those of a Chief Medical Officer (CMO). He will also continue with his current role as a member of the Board of Directors. Dr. Tendler will work with the Company to oversee clinical development strategy and operations of the company's pipeline, including its VISTA inhibiting antibody, TBS-2025.From the news:
"Craig has been an active and valued member of our Board and enthusiastically agreed to provide strategic, operational and other related services consistent with those of a CMO. His decades of clinical and regulatory experience in accelerating drug development across therapeutic areas, notably in hematologic malignancies, will be of particular value to our TBS-2025 program," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "I am confident that his recent leadership role and strategic contributions to JNJ's menin inhibitor, bleximenib in NPM1 mutated AML, will prove invaluable to our regulatory pathway and development of TBS-2025 in AML and other blood related cancers. I look forward to working with Craig as we unlock the value in VISTA and other clinical programs."Dr. Craig Tendler added, "I am excited about the potential benefits of TBS-2025 for blood- related cancers where the negative checkpoint, VISTA, has been implicated in playing a critical immunosuppressive role in both therapy failure and poor overall survival in AML, particularly in the molecularly defined subset of NPM1 mutated AML. We have already received preliminary feedback from the Division of Hematologic Malignancies I of the FDA on the early development plan and will continue to work closely with the Agency to accelerate the clinical development of TBS-2025, both as monotherapy and in combination with menin inhibitors, an area where I have substantial experience."TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.On March 16th, AstraZeneca (NYSE: AZN) reported that Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the European Union (EU) for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The regimen includes two cycles of Imfinzi in combination with chemotherapy before and after surgery, followed by Imfinzi monotherapy.From the news:
The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on the positive results from the MATTERHORN Phase III trial, which were published in The New England Journal of Medicine.Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million people diagnosed each year. In 2024, there were roughly 15,500 drug-treated patients in the EU with early-stage and locally advanced gastric or GEJ cancer.Josep Tabernero, MD, PhD, head of the Medical Oncology Department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Spain, and principal investigator in the trial, said: "Despite curative-intent surgery and chemotherapy, patients with resectable gastric and gastroesophageal cancers still face high recurrence rates and an urgent need for improved long-term survival. In MATTERHORN, nearly 70 per cent of patients were still alive three years after treatment with the durvalumab-based perioperative regimen. This EU approval brings patients the first immunotherapy regimen to extend survival in this early setting and is poised to become the new standard of care."Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: "This approval marks our third perioperative approval in Europe for an Imfinzi-based regimen, underscoring AstraZeneca's commitment to transforming outcomes in early-stage disease, where cure is possible. For patients with early gastric and gastroesophageal cancers, this immunotherapy-based regimen delivers a durable survival benefit that increases over time."In a planned interim analysis, patients treated with the Imfinzi-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone (based on an event-free survival [EFS] hazard ratio [HR] of 0.71; 95% confidence interval [CI] 0.58-0.86; p

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic OpportunitiesMarch 12, 2026 8:01 AM
PR Newswire (US)

SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process.The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities. Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Company.James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon stated, "The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial. Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review. At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders."The Company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process. The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.About Maxim Group LLCFounded in 2002, Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan providing a comprehensive array of financial services including investment banking, global institutional sales, equity research, fixed income and derivative sales & trading, merchant capital, private wealth management, and prime brokerage services to a diverse range of corporate clients, institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB). To learn more about Maxim Group, visit www.maximgrp.com.About Aethlon Medical, Inc.Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, without limitation, statements regarding the Company's engagement of Maxim Group LLC, the exploration or identification of potential strategic merger and acquisition alternatives, the possibility, timing or structure of any transaction, and the potential benefits of any such transaction. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. There can be no assurance that the Company's engagement of a financial advisor will result in the identification or consummation of any transaction. The Company may determine to suspend or terminate the exploration of strategic alternatives at any time, and no timetable has been set for completion of this process. Risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements include, without limitation: the Company's ability to identify suitable transaction partners; the risk that any discussions with third parties do not result in a definitive agreement; the risk that a transaction, if agreed upon, is not consummated; potential disruption to the Company's business as a result of the announcement or pendency of a strategic review process; the diversion of management's time and attention; the Company's ability to maintain compliance with Nasdaq listing standards; the Company's ability to raise additional capital; and other risks and uncertainties described under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances or disclose developments. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any securities that may be offered in connection with a potential transaction would be offered only pursuant to an effective registration statement or in reliance upon an applicable exemption from registration requirements.Company Contacts:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.comInvestor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com



View original content:https://www.prnewswire.com/news-releases/aethlon-medical-engages-maxim-group-llc-to-evaluate-strategic-opportunities-302711837.htmlSOURCE Aethlon Medical, Inc.

Original: Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate UpdateFebruary 12, 2026 4:15 PM
PR Newswire (US)

Clinical and research programs continue to advance, supported by year-to-date cost efficienciesConference Call Today at 4:30 p.m. ETSAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments. Key HighlightsMaintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology trial is actively progressing, reflecting continued clinical execution.Scientific Advancement: Continued advancement of the Company's preclinical extracellular vesicle (EV) research platform, including Long COVID data published on bioRxiv and submitted for peer review, supporting the Hemopurifier's potential as a multi-indication therapeutic approach and a "pipeline within a single device".Technology Development: Continued evaluation of Hemopurifier® (HP) compatibility with a simplified blood treatment system to support broader potential clinical application over time.Operational Efficiency: Maintained disciplined cost controls, resulting in lower year-to-date operating expenses compared to prior year.Clinical and Corporate UpdateClinical Progress in Cancer TrialEnrollment and treatment of participants in Cohort 2 of the Australian oncology trial is actively underway, building on Cohort 1, which demonstrated favorable directional improvements in extracellular vesicle and immune cell numbers, as well as safety and tolerability. This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®.Technology Development:Under a Material Transfer Agreement (MTA), Stavro is evaluating the compatibility of the Hemopurifier with their SLAMB system, a simplified blood treatment platform. We believe this research may support future Hemopurifier use in oncology units and infusion centers without requiring a large dialysis catheter, dialysis machines, or supervising nephrologist.Scientific Advancement:The Aethlon R&D team continues to build on our pre-clinical Long COVID research, which demonstrated that the GNA affinity resin binds EVs from Long COVID patient samples and reduces microRNAs associated with immune dysregulation. These findings were published on bioRxiv and have been submitted for consideration in a peer-reviewed journal. We are also exploring other cargo in these EVs, that may be removed by the Hemopurifier.EVs, including platelet-derived EVs, have been implicated in a range of diseases beyond cancer, such as Lupus, Rheumatoid arthritis, Systemic Sclerosis, Multiple Sclerosis, Cardiovascular Diseases, Sepsis and ALS. Aethlon previously published preclinical data demonstrating removal of platelet derived EVs from healthy plasma by the Hemopurifier and plan to extend this work by investigating the removal of platelet-derived EVs and microRNAs by the Hemopurifier in plasma from patients with select indications. We believe this work reflects the potential of the Hemopurifier as "a pipeline within a single device."Operational AchievementsOperating expenses declined 26.9% during the nine months ended December 31, 2025, reflecting the Company's ongoing efforts to optimize costs while advancing its clinical and research programs."We remain committed to advancing our clinical programs and research initiatives with operational discipline," said James Frakes, CEO and CFO of Aethlon Medical. "Recent progress in our trials, research collaborations, and technology development continues to move us closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases."Financial Results for the Fiscal Third Quarter Ended December 31, 2025As of December 31, 2025, Aethlon had a cash balance of approximately $7.0 million.Consolidated operating expenses for the three months ended December 31, 2025 were approximately $2.06 million, up $250,000, or 13.6%, from $1.81 million in the same period in 2024. The increase was primarily driven by higher payroll and related costs, which rose by approximately $367,000, partially offset by $75,000 decrease in general and administrative expenses, primarily due to lower clinical trial costs, and an approximate $45,000 decrease in professional fees primarily due to reduced investor relations expenses.As a result, the operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period.Other income, primarily interest income earned on cash balances, totaled $44,000 for the three months ended December 31, 2025, compared to $60,000 in the prior-year period.Financial Results for the Nine Months Ended December 31, 2025Consolidated operating expenses for the nine months ended December 31, 2025 were approximately $5.36 million compared to approximately $7.34 million for the same period in 2024. This decrease of approximately $1.98 million, or 26.9%, in the 2025 period was due to decreases in payroll and related expenses of approximately $1.09 million, general and administrative expenses of $527,000 and professional fees of $361,000.The consolidated balance sheets for December 31, 2025 and March 31, 2025, along with the consolidated statements of operations for the three and nine months ended December 31, 2025 and 2024, are included at the end of this release.Conference CallManagement will host a conference call today, Thursday, February 12, 2026, at 4:30 p.m. ET to review the Company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034a255186. Please note that registered participants will receive their dial-in number upon registration.Interested parties without internet access or unable to pre-register may dial in by calling:PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442All callers should ask for the Aethlon Medical, Inc. conference call.A replay of the call will be available approximately one hour after the end of the call through March 12, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 3024961.About the Hemopurifier®The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for:The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.About Aethlon Medical, Inc.Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company's ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia s; the timing, scope, design, and potential outcomes or interpretation of such studies; the Company's ability to manufacture the Hemopurifier in sufficient quantities for clinical and potential future commercial use; the availability and adequacy of capital to support ongoing operations; and the Company's ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to maintain its Nasdaq listing, the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters.Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.comInvestor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com 






AETHLON MEDICAL, INC. AND SUBSIDIARYCondensed Consolidated Balance Sheets













ASSETS









December 31, 2025
March 31, 2025
CURRENT ASSETS





Cash and cash equivalents
$                       6,956,397
$                                5,501,261

Prepaid expenses and other current assets
185,122
448,539








TOTAL CURRENT ASSETS
7,141,519
5,949,800








Property and equipment, net
434,179
676,220

Operating lease right-of-use asset, net
382,583
601,846

Patents, net
138
550

Restricted cash
98,709
97,813

Deposits
-
33,305








TOTAL ASSETS
$                   8,057,128
$                           7,359,534














LIABILITIES AND STOCKHOLDERS' EQUITY






CURRENT LIABILITIES





Accounts payable 
$                          469,452
$                                    534,524

Due to related parties
237,846
579,565

Operating lease liability, current portion
330,628
313,033

Other current liabilities
219,211
472,164








TOTAL CURRENT LIABILITIES
1,257,137
1,899,286








Operating lease liability, less current portion
86,894
336,718








TOTAL LIABILITIES
1,344,031
2,236,004







STOCKHOLDERS' EQUITY












Common stock, par value $0.001 per share; 6,000,000 shares authorized as of December
31, 2025 and March 31, 2025; 973,213 shares issued and outstanding as of December 31,
2025 and 258,531 shares issued and 201,074 outstanding at March 31, 2025.






973
259

Additional paid-in capital
179,963,981
173,095,221

Accumulated other comprehensive loss
(29,837)
(17,133)

Accumulated deficit
(173,222,020)
(167,954,817)








TOTAL STOCKHOLDERS' EQUITY 
6,713,097
5,123,530








TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$                   8,057,128
$                           7,359,534
 








AETHLON MEDICAL, INC. AND SUBSIDIARY Consolidated Statements of OperationsFor the three and nine month periods ended December 31, 2025 and 2024




























Three Months
Three Months
Nine Months
Nine Months

Ended 12/31/25
Ended 12/31/24
Ended 12/31/25
Ended 12/31/24








OPERATING EXPENSES







Professional fees
$        333,042
$          377,877
$    1,202,870
$    1,563,995Payroll and related expenses
987,424
620,487
2,163,036
3,248,187General and administrative
741,650
816,383
1,998,429
2,525,220    Total operating expenses
2,062,116
1,814,747
5,364,335
7,337,402








OPERATING LOSS
(2,062,116)
(1,814,747)
(5,364,335)
(7,337,402)








INTEREST INCOME, NET
43,871
59,964
97,132
204,206








NET LOSS 
(2,018,245)
(1,754,783)
(5,267,203)
(7,133,196)








OTHER COMPREHENSIVE LOSS
(3,460)
(13,057)
(12,704)
(10,085)








COMPREHENSIVE LOSS
$(2,021,705)
$(1,767,840)
$(5,279,907)
$(7,143,281)








Basic and diluted loss per share attributable to 







  common stockholders
$          (2.45)
$          (10.05)
$        (11.01)
$        (48.35)

















Weighted average number of common shares outstanding - basic and diluted823,126
174,529
478,310
147,520 



View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-fiscal-q3-2026-financial-results-and-corporate-update-302685564.htmlSOURCE Aethlon Medical, Inc.

Original: Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026February 4, 2026 8:01 AM
PR Newswire (US)

SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026.Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034a255186. Please note that registered participants will receive their dial-in number upon registration.Interested parties without internet access or unable to pre-register may dial in by calling:PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442All callers should ask for the Aethlon Medical, Inc. conference call.A replay of the call will be available approximately one hour after the end of the call through March 12, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 3024961.About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.Additional information can be found at www.AethlonMedical.com.Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Risks and uncertainties include, but are not limited to, clinical trial outcomes, regulatory approvals, the ability to obtain additional financing, and market acceptance of the Company's products, as more fully described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com  



View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-third-quarter-financial-results-and-host-conference-call-on-february-12-2026-302678752.htmlSOURCE Aethlon Medical, Inc.

Original: Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

Well, as you can tell from my post, I'll never buy again... 2 RS in 4 Months... The CEO needs an appointment with a Woodchipper.

That was last month. PPS going up since then.
Will be buying more.

Thanks. the super low AS and OS will attract buyers after the reaction. Vamos a ver.

https://www.investing.com/news/sec-filings/aethlon-medical-enacts-1for10-reverse-stock-split-effective-thursday-93CH-4292446

Interesting article on the systematic loss of health independence.
https://interestofjustice.substack.com/p/the-unscrupulous-global-syndicate?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff65f168f-34e0-4e69-802b-bcf1896004ef_1536x1024.png&open=false

Looks like things are improving bit by bit both in the product and in the internal fiscal arena per released financials.

I didn't hear about that. Do you have a link? Gracias

Well, yet ANOTHER RS is happening. Barely 4 Months since the last.

These Pieces of Shit need to be dragged behind the Woodshed.

$AEMD is a bottomed penny with no offering risk and confirmed cancer data coming this month, fresh 13g filing and very high CTB percentage.

- Hemopurifier Phase 1 Cancer initial lab observations from the first patient cohort expected in September 2025.

Initial observations from the analysis of central lab samples from the first patient cohort in the Australian trial are expected to be available in September 2025.

- 7.7% 13g filing out this morning

- It is post-offering ( which was at nice premium as well ) and it's closed already so no risk of near term offer.

Closing of the offering expected on September 5, 2025.

- It is on Reg SHO Threshold List - so shorts are very limited here

- has massive 800% CTB & just 4k borrows on IBKR

$AEMD

Hope people hold tomorrow. Miniscule float... I remember it went to almost $11 in 2021...

grabbed cupr. 😉

Good morning gail 😃 Nice 🤑
(Sold 3/4)

$AEMD

i may get back in on the….

….

dip, not sure yet.

yup, that was fun!

$2.72 😃

$AEMD

wowza, working its way to 3 bucks!!

omg, just flew past 2 bucks, wow!!

this ran huge in jan, maybe history repeats?

we have boomage, weeee!!!

wow, 1.75 was a bit…..

…

fat on the ask but someone took them out, do the wood shed, lol. going up now.

its trying to move up now.

gabbed some here.

Too bad there isn't people holding. Computerized micro trading all day won't do anything.

AMED...................................................................p/m

Offering withdrawal is great news!

ILLR Form RW Triller Group Inc.
06:08:00 AM ET, 08/20/2025 - US Securities and Exchange Commission
http://archive.fast-edgar.com/20250820/AK2TG22CLZ22MTAZ2IZN2ZY2TBOQZ222Z276

Filed on: August 20, 2025

$AEMD

SP is holding on the Overnight market at $1.60...

Ok. Never heard of them, but I'll never buy a penny again anyway.

Almost 3 times the float just in the AH here... Tomorrow could be crazy or could flop...

IVP...PALI...LIXT.. 🥳...all withdrew their S1and there are more...

Never seen a company withdraw an offering before.

I don't even know what to say.

AEMD $1.70 + 50% cash out time maybe it does a Greek god move like THAR $5 + 300% 

AEMD $1.28 pumping on S-1 news 

Withdrew offering no dumps for now $1.47 + 34%

AEMD.............................................................a/h

Anyone make the conference call yesterday? Replay available.

AEMD.............................https://stockcharts.com/h-sc/ui?s=AEMD&p=W&b=5&g=0&id=p86431144783